Triplet combination of durvalumab, tremelimumab, and paclitaxel in biliary tract carcinomas: Safety run-in results of the randomized IMMUNOBIL PRODIGE 57 phase II trial

Efficacy and safety of nivolumab for metastatic biliary tract cancer

(2019) Miaomiao Gou et al.   OncoTargets and Therapy

Pembrolizumab (pembro) for advanced biliary adenocarcinoma: Results from the KEYNOTE-028 (KN028) and KEYNOTE-158 (KN158) basket studies.

(2019) Yung-Jue Bang et al.   JOURNAL OF CLINICAL ONCOLOGY

Completely resolved advanced biliary tract cancer after treatment by pembrolizumab: a report of two cases

(2019) Osama M. Alshari et al.   OncoTargets and Therapy

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

(2018) Mark A. Socinski et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer

(2018) Luis Paz-Ares et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial

(2018) Frank Stephen Hodi et al.   LANCET ONCOLOGY

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

(2018) Peter Schmid et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immune checkpoint inhibitors and elderly people: A review

(2017) Amaury Daste et al.   EUROPEAN JOURNAL OF CANCER

iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics

(2017) Lesley Seymour et al.   LANCET ONCOLOGY

Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†

(2016) J. W. Valle et al.   ANNALS OF ONCOLOGY

525 Safety and efficacy of pembrolizumab (MK-3475) in patients (pts) with advanced biliary tract cancer: Interim results of KEYNOTE-028

(2015) Y.J. Bang et al.   EUROPEAN JOURNAL OF CANCER

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

Repeated PD-1/PD-L1 monoclonal antibody administration induces fatal xenogeneic hypersensitivity reactions in a murine model of breast cancer

(2015) Christine Mall et al.   OncoImmunology

Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma

(2014) John Bridgewater et al.   JOURNAL OF HEPATOLOGY

Immunological off-target effects of standard treatments in gastrointestinal cancers

(2013) A. G. Duffy et al.   ANNALS OF ONCOLOGY

Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer

(2013) L Bracci et al.   CELL DEATH AND DIFFERENTIATION

Phase II Trial of Erlotinib and Docetaxel in Advanced and Refractory Hepatocellular and Biliary Cancers: Hoosier Oncology Group GI06-101

(2011) E. G. Chiorean et al.   ONCOLOGIST

Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer

(2010) Juan Valle et al.   NEW ENGLAND JOURNAL OF MEDICINE

Paclitaxel acts as an adjuvant to promote both Th1 and Th2 immune responses induced by ovalbumin in mice

(2010) Lin Yuan et al.   VACCINE

Chemopreventive agents induce programmed death-1-ligand 1 (PD-L1) surface expression in breast cancer cells and promote PD-L1-mediated T cell apoptosis

(2007) Ping Zhang et al.   MOLECULAR IMMUNOLOGY